{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:05Z","timestamp":1792854185819,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtha.2022.11.039","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:24:18Z","timestamp":1674642258000},"page":"1020-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment\u2014a prospective cohort study"],"prefix":"10.1016","volume":"21","author":[{"given":"Wobke E.M.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke C.","family":"Poolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"Koene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fijnheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther R.","family":"van Bladel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin P.M.","family":"van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.G.","family":"Schutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.11.039_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib2","first-page":"16","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2022.11.039_bib3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.11.039_bib4","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.11.039_bib5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"Schifferli","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14057","article-title":"The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia","volume":"75","author":"Oka","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jtha.2022.11.039_bib7","first-page":"97","article-title":"Cytokines and chemokines in patients with chronic immune thrombocytopenia (ITP) treated with TPO-receptoragonists (TPO-ra) compared to healthy controls","volume":"96","author":"Gudbrandsdottir","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.11.039_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia\u2014current status and future perspectives","volume":"194","author":"Swan","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2021010735","article-title":"Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53209-y","article-title":"Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia","volume":"9","author":"Lozano","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2022.11.039_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib13","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.V114.22.2423.2423","article-title":"Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura","volume":"114","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"Kuter","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib18","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/bloodadvances.2017007989","article-title":"ITP and thrombosis: an intriguing association","volume":"1","author":"Rodeghiero","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.11.039_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.11.039_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107602969800400201","article-title":"Sticky platelet syndrome: a common cause of unexplained arterial and venous thrombosis","volume":"4","author":"Bick","year":"1998","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1055\/s-0033-1353394","article-title":"Sticky platelet syndrome","volume":"39","author":"Kubisz","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107602969500100111","article-title":"Ten years\u2019 experience with the \u201csticky platelet syndrome","volume":"1","author":"Mammen","year":"1995","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib23","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.1073\/pnas.250475997","article-title":"Pro-coagulant state resulting from high levels of soluble P-selectin in blood","volume":"97","author":"Andr\u00e9","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2022.11.039_bib24","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"van Dijk","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.11.039_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.20020945","article-title":"A\u00a0crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in\u00a0vivo","volume":"197","author":"Massberg","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtha.2022.11.039_bib27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jama.299.11.1306","article-title":"Gene variants associated with deep vein thrombosis","volume":"299","author":"Bezemer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2022.11.039_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2022.11.039_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"van Dijk","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.11.039_bib30","first-page":"22","article-title":"Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists","volume":"31","author":"Garabet","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2022.11.039_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000447","article-title":"Pathophysiology of immune thrombocytopenia","volume":"25","author":"Li","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.679934","article-title":"Thrombin generation as a method to identify the risk of bleeding in high clinical-risk patients using dual antiplatelet therapy","volume":"8","author":"de Breet","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2022.11.039_bib33","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1182\/blood-2012-06-437723","article-title":"A\u00a0novel flow cytometry-based platelet aggregation assay","volume":"121","author":"De Cuyper","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/vox.12557","article-title":"Agonist-induced platelet reactivity correlates with bleeding in haemato-oncological patients","volume":"112","author":"Batman","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtha.2022.11.039_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2022.11.039_bib36","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1538-7836.2006.01967.x","article-title":"The limits of simulation of the clotting system","volume":"4","author":"Wagenvoord","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib37","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1017\/S0022149X19000798","article-title":"Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren","volume":"94","author":"Mebius","year":"2020","journal-title":"J\u00a0Helminthol"},{"key":"10.1016\/j.jtha.2022.11.039_bib38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1538-7836.2010.03786.x","article-title":"High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study","volume":"8","author":"Snoep","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib39","series-title":"Linear mixed models in linguistics and psychology: a comprehensive introduction","article-title":"From the paired t-test to the linear mixed model","author":"Vasishth","year":"2022"},{"key":"10.1016\/j.jtha.2022.11.039_bib40","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jclinepi.2006.01.014","article-title":"Review: a gentle introduction to imputation of missing values","volume":"59","author":"Donders","year":"2006","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtha.2022.11.039_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","article-title":"Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods","volume":"86","author":"Aickin","year":"1996","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jtha.2022.11.039_bib42","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2156-15-S1-S5","article-title":"Holm multiple correction for large-scale geneshape association mapping","volume":"15","author":"Fu","year":"2014","journal-title":"BMC Genetics"},{"key":"10.1016\/j.jtha.2022.11.039_bib43","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood.V120.21.1096.1096","article-title":"Elevated plasma Von Willebrand factor and decreased ADAMTS13 antigen levels in patients with immune thrombocytopenia (ITP)","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/09537104.2013.869312","article-title":"Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura","volume":"26","author":"Kim","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2022.11.039_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00320876","article-title":"Increased factor VIII\/vWf levels in patients with reduced platelet number","volume":"54","author":"Casonato","year":"1987","journal-title":"Blut"},{"key":"10.1016\/j.jtha.2022.11.039_bib46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2022.11.039_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2020003135","article-title":"Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism","volume":"5","author":"Edvardsen","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.11.039_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2022.11.039_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.thromres.2019.04.033","article-title":"A\u00a0review of global coagulation assays\u2014is there a role in thrombosis risk prediction?","volume":"179","author":"Lim","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.11.039_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00424-007-0411-3","article-title":"How steroid hormones act on the endothelium\u2014insights by atomic force microscopy","volume":"456","author":"Hillebrand","year":"2008","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jtha.2022.11.039_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211054514","article-title":"Endothelial activation and immune thrombocytopenia: an engagement waiting for consolidation","volume":"27","author":"Efat","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2019.11.031","article-title":"Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists","volume":"185","author":"Garabet","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.11.039_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjh.14412","article-title":"Procoagulant profile in patients with immune thrombocytopenia","volume":"175","author":"\u00c1lvarez-Rom\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib54","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1172\/JCI111789","article-title":"A\u00a0monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells","volume":"75","author":"Thiagarajan","year":"1985","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2022.11.039_bib55","first-page":"27","article-title":"Evidence that platelet-derived microvesicles may transfer platelet-specific immunoreactive antigens to the surface of endothelial cells and CD34+ hematopoietic stem\/ progenitor cells--implication for the pathogenesis of immune thrombocytopenias","volume":"45","author":"Majka","year":"2007","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1016\/j.jtha.2022.11.039_bib56","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1182\/blood.V73.5.1235.1235","article-title":"Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex","volume":"73","author":"Giltay","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/09537104.2017.1378807","article-title":"Endothelial alterations in a canine model of immune thrombocytopenia","volume":"30","author":"LeVine","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2022.11.039_bib58","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.trsl.2015.09.005","article-title":"Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura","volume":"166","author":"Chiou","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.jtha.2022.11.039_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tmrv.2014.03.001","article-title":"Platelet receptor expression and shedding: glycoprotein Ib-IX-V and glycoprotein VI","volume":"28","author":"Gardiner","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2022.11.039_bib60","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database","volume":"95","author":"Sarpatwari","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.11.039_bib61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2019.04.016","article-title":"Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia\u2014results from two nationwide cohorts","volume":"178","author":"Ekstrand","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.11.039_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.2830080402","article-title":"Plasma beta-thromboglobulin values in thrombocytopenic patients with acute leukemia","volume":"8","author":"Kutti","year":"1980","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cca.2008.09.018","article-title":"Soluble P-selectin as a marker of in\u00a0vivo platelet activation","volume":"399","author":"Ferroni","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jtha.2022.11.039_bib64","series-title":"Platelet Protocols. Amsgterdam","first-page":"27","article-title":"Laboratory evaluation of platelet function","author":"McCabe White","year":"1999"},{"key":"10.1016\/j.jtha.2022.11.039_bib65","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bjh.16459","article-title":"Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation","volume":"189","author":"Monz\u00f3n Manzano","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-017-0413-3","article-title":"Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia","volume":"10","author":"Tao","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtha.2022.11.039_bib67","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","article-title":"Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in\u00a0vitro platelet function","volume":"37","author":"Erhardt","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib68","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.V95.8.2514","article-title":"Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers","volume":"95","author":"Harker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib69","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib70","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/09537104.2017.1394451","article-title":"Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia","volume":"30","author":"Garabet","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2022.11.039_bib71","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bcp.12370","article-title":"Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia","volume":"78","author":"\u00c1lvarez Rom\u00e1n","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2022.11.039_bib72","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2012.09227.x","article-title":"Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists","volume":"158","author":"Ghanima","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH13-10-0873","article-title":"Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia","volume":"112","author":"\u00c1lvarez Rom\u00e1n","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib74","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1160\/TH07-09-0581","article-title":"Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma","volume":"99","author":"Duchemin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib75","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1055\/s-0037-1615964","article-title":"The role of factor XI in thrombin generation induced by low concentrations of tissue factor","volume":"85","author":"Keularts","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"Dielis","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.11.039_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-140385","article-title":"Application of Thrombomodulin-thrombin generation to diverse abnormalities of the protein C system","volume":"136","author":"Manco-Johnson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib78","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A\u00a0reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.11.039_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2022.11.039_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jgh.13244","article-title":"Novel functions of platelets in the liver","volume":"31","author":"Kurokawa","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2022.11.039_bib81","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.21037\/apm-21-1067","article-title":"Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jtha.2022.11.039_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2017.00059","article-title":"The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin","volume":"8","author":"Varghese","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jtha.2022.11.039_bib83","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1634\/stemcells.21-3-272","article-title":"A\u00a0role for thrombopoietin in hemangioblast development","volume":"21","author":"Perlingeiro","year":"2003","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtha.2022.11.039_bib84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2141.1997.1222936.x","article-title":"Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey I. Illustrative reference ranges by age, sex and hormone use","volume":"97","author":"Lowe","year":"1997","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622078205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622078205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:28Z","timestamp":1761536248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622078205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1538783622078205"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.11.039","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment\u2014a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}